SCHEMBL1018158

SCHEMBL1018158

Cc1ccc(N[C@H]2CC[C@H](NC(=O)OC(C)(C)C)C2)c([N+](=O)[O-])c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 3/20 0.48
DRD2 P14416 1/20 0.43
NPC1 O15118 2/20 0.43
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RAB9A P51151 1/20 0.41
KDM1A O60341 1/20 0.40
MAOB P27338 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
BTK Q06187 2/20 0.39
KCNMA1 Q12791 1/20 0.39
KMT2A Q03164 2/20 0.39
MAPT P10636 2/20 0.39
WNK1 Q9H4A3 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1018157 1.00 HCAR3 (0.48) HCAR3DRD2NPC1ALDH1A1SMN1; SMN2
SCHEMBL1018156 1.00 HCAR3 (0.48) HCAR3DRD2NPC1ALDH1A1SMN1; SMN2
SCHEMBL1015486 0.94 HCAR3 (0.53) HCAR3DRD2NPC1ALDH1A1SMN1; SMN2
SCHEMBL1015485 0.94 HCAR3 (0.53) HCAR3DRD2NPC1ALDH1A1SMN1; SMN2
SCHEMBL25674713 0.85 HCAR3 (0.49) HCAR3RAB9ABTKKMT2AMAPT
SCHEMBL18927034 0.82 KDM1A (0.43) DRD2KDM1AMAOBLMNANPSR1
SCHEMBL1015186 0.82 KDM1A (0.43) DRD2KDM1AMAOBLMNANPSR1
SCHEMBL18927030 0.82 KDM1A (0.43) DRD2NPC1RAB9AKDM1AMAOB
SCHEMBL1015184 0.82 KDM1A (0.43) DRD2KDM1AMAOBLMNANPSR1
SCHEMBL1015183 0.82 KDM1A (0.43) DRD2KDM1AMAOBLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089368-B1 DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-01-12 EP disclosed
US-7652053-B2 Diaminocycloalkane MCH receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2010-01-26 US disclosed
US-20080146636-A1 For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol ERICKSON SHAWN DAVID 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146636-A1 For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol GPR119, GIPR, EBP HCAR3 1299/4885DRD2 330/4885NPC1 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.